ClinicalTrials.gg
RecruitingNCT07926347Updated Nov 10, 2026

Functional Reorganization and Recovery of the Language and Domain-general Multiple Demand Systems in Aphasia

An interventional study of Constant Therapy program in Aphasia, sponsored by Boston University Charles River Campus. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Treatment

Updated Nov 10, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The objective of this study is to apply state-of-the art brain imaging approaches to evaluate new hypotheses about the contributions of core linguistic vs. domain-general executive systems to language processing and recovery in patients with varying degrees of linguistic impairment. Specifically, the investigators will first characterize the degree to which standard language assessments tax the domain-general Multiple Demand (MD) network (Aim 1). And then systematically investigate the causal contributions of the language and the MD networks to language processing and aphasia recovery in patients of varying severity (Aims 2 and 3).

02

Conditions studied

  • Aphasia

Browse trials for

Keywords

  • Constant Therapy program
  • Psychotherapy
  • Lifestyle counseling
  • Lesion load
03

In context

Aphasia

338 studies on the registry are indexed under Aphasia; 95 are open to participants now.

This study's planned enrollment of 100 is above the median of 30 across 298 interventional studies indexed under Aphasia.

Browse Aphasia studies →

Lead sponsor

Boston University Charles River Campus is the lead sponsor of 159 studies on the registry; 33 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 9 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 12 weeks post-stroke at time of study enrolment
  • medically and neurologically stable (no active seizures for 6 months) and at least wheelchair ambulatory
  • premorbid fluency in English
  • a family member or caregiver available to assist in study setup and in communicating with study staff

Exclusion criteria

Exclusion Criteria:

  • a major, active neurological condition other than stroke, as determined by medical record review
  • history of cognitive impairment unrelated to stroke, such as dementia
  • history of symptomatic stroke prior to index stroke
  • severe uncorrected vision and/or hearing problems likely to impact study participation
  • comorbid learning or language disorder diagnosed prior to stroke or as a child
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Immediate treatment

    Participants randomized to this arm will receive the intervention immediately after baseline behavioral and neural procedures.

    Behavioral: Constant Therapy program

  • Active comparator
    Delayed treatment

    Participants randomized to this arm will be put on a waitlist for 5 weeks and will then receive the intervention.

    Behavioral: Constant Therapy program

Interventions

  • BehavioralConstant Therapy program

    The Constant Therapy program includes includes 91 therapy exercise programs and participants can practice any of the exercises in the program for 50 hours (60 minutes a day, 5 days a week for 10 weeks).

06

What researchers measure

Primary outcomes

  1. Change in the Western Aphasia Battery Revised Aphasia Quotient

    The Western Aphasia Battery Revised Aphasia Quotient (WAB-R-AQ) is a standardized, gold-standard assessment for determining the presence, type, and severity of post-stroke aphasia. The WAB-R measures performance across a variety of expressive and receptive language domains. Weighted performance across four of these domains, namely spontaneous speech, auditory verbal comprehension, repetition, and naming/word finding, yields the WAB-R AQ, a composite score that ranges from 0 to 100, with higher scores indicating better language function.

    Time frame: Baseline, immediately after the 10-week intervention

Secondary outcomes

  1. Western Aphasia Battery- Revised Language Quotient (WAB-R LQ)

    The WAB-R measures performance across a variety of expressive and receptive language domains and takes approximately 45-60 minutes to administer. Weighted performance across four of these domains - spontaneous speech, auditory verbal comprehension, repetition, and naming/word finding - yields a composite score, the WAB-R Aphasia Quotient (AQ). The WAB-R AQ is an impairment-based metric that reliably indexes aphasia severity across different aphasia subtypes, making it ideal as a metric for studies with heterogenous patient samples as for the current study. In addition to the AQ, Language Quotients (LQ) can be obtained from a full administration of the WAB-R. LQ is a summary score encompassing both spoken and written language abilities. The LQ is scaled from 0 to 100, where higher numbers reflect stronger overall performance across the tested domains.

    Time frame: Baseline, immediately after the 10-week intervention

  2. Western Aphasia Battery- Revised Cortical Quotient (WAB-R CQ)

    The Cortical Quotient (CQ) is a summary score taking into account all subtests of the WAB-R, including not only spoken and written language but also apraxia, constructional, visuospatial and calculation tasks. Administration of tests to calculate CQ and LQ together take approximately 45 minutes. The CQ is scaled from 0 to 100, where higher numbers reflect stronger overall performance across the tested domains.

    Time frame: Baseline, immediately after the 10-week intervention

  3. Boston Naming Test (BNT)

    The BNT is one of the most widely used measures of confrontational naming, consisted of 60 line drawings of objects of graded difficulty. It consists of 60 black and white pictures that increase in the order of difficulty (pictures progressively include less frequent words). Scoring comprises accuracy out of 60 items. A point is typically given for items named spontaneously or correctly after a semantic cue (a category or description hint). For healthy, non-brain-damaged adults, average raw scores generally range from 50 to 59 out of 60, depending on age and education level (with normative means clustering around 53 to 55).

    Time frame: Baseline, immediately after the 10-week intervention

  4. Pyramids and Palm Trees Test (PPTT)

    The PPTT is a visual semantic association task designed to assess semantic memory and the ability to form and retrieve associations between concepts. For each triad, a target stimulus (e.g., a picture or word of a pyramid) is shown at the top, and two choice options (e.g., a palm tree vs. a fir tree) are shown at the bottom. The subject must point to or select the item that semantically matches the target. There are 52 trials. A score of 47 or higher (90% or better: ≥ 47/52) is generally considered normal, indicating no clinically significant semantic memory deficit. A score below 47 (less than 90%) indicates a clinically significant semantic memory impairment.

    Time frame: Baseline, immediately after the 10-week intervention

  5. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    The RBANS provides a comprehensive assessment of general cognitive skills, including attention, memory, executive function, and visuospatial processing. The battery consists of 12 short subtests divided across five specific cognitive domains: Immediate Memory: List Learning, Story Memory, Visuospatial/Constructional: Figure Copy, Line Orientation, Language: Picture Naming, Semantic Fluency, Attention: Digit Span, Coding, Delayed Memory: List Recall, List Recognition, Story Recall, Figure Recall. Reported total scores range from 40 to 160, with scores 120 or higher as superior performance.

    Time frame: Baseline, immediately after the 10-week intervention

  6. Reading Comprehension Battery for Aphasia-2 (RCBA-2)

    The RCBA-2 provides a comprehensive evaluation of the nature and degree of reading impairments at single word-, sentence- and paragraph-level. Lower total scores indicate more severe acquired reading impairments (alexia) associated with aphasia or brain injury. Total score is 0-100 (10 core subtests), typical range is 97.32, whereas aphasic patients tend to score 18-99.

    Time frame: Baseline, immediately after the 10-week intervention

  7. Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39)

    The SAQOL-39 consists of 39 questions to assess health-related quality of life in individuals with chronic post-stroke aphasia with responses from 1 = Could not do it at all to 5 = No trouble at all. To calculate the scores, the mean (average) value rather than a cumulative sum is calculated and higher means suggest higher quality of life

    Time frame: Baseline, immediately after the 10-week intervention

07

Study locations

1 of 1 sites recruiting
  • Center for Brain Recovery, BU Charles River Campus
    Boston, Massachusetts 02215, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2031, 55 months later.

Of 183 non-industry interventional studies with no phase under Aphasia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 55 months is above that.

Counting every sponsor, half of 185 studies reached it within 36 months; a quarter within 20 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 9, 2026
StartEst.
Dec 2026
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2032
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
Center for Brain Recovery, BU Charles River Campus is now Recruiting
Nov 10, 2026
Registered
First appeared on the registry
Nov 9, 2026
Show all 2 updates
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    Center for Brain Recovery, BU Charles River Campus is now Recruiting
  2. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07926347
Responsible party
Sponsor
First posted
Nov 9, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jul 2031 (estimated)
Completion
Jul 2032 (estimated)
Last update
Nov 10, 2026

Study contacts

Swathi Kiran, PhD
Contact
kirans@bu.edu
617-358-5478
Swathi Kiran, PhD
principal investigator · BU Charles River Campus, Center for Brain Recovery
Evelina Fedorenko, PhD
principal investigator · Massachusetts Institute of Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion